24-Week Open Label Extension to a Randomized, 6-Week Double Blind, Placebo Controlled Study, to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROSĀ® Paliperidone in the Treatment of Geriatric Subjects With Schizophrenia
PHASE3
The purpose of this open-label study was to evaluate the safety and tolerab...
A 52-week, Open-label Extension Study Following a 6-week, Double-blind, Placebo- and Active- Controlled Study (R076477-SCH-303) to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia
PHASE3
The purpose of the study was an Open Label Extension to a completed study t...
A 52 Week Open Label Extension Trial Following the Recurrence Prevention Study R076477-SCH-301 to Evaluate the Safety and Tolerability of Paliperidone ER in Subjects With Schizophrenia.
PHASE3
The purpose of the study was an Open Label Extension to the recurrence prev...